References

1. Semaglutide (Ozempic/Wegovy) — efficacy and treatment profile

Wilding JPH, Batterham RL, Calanna S, et al., for the STEP 1 Study Group. Once-Weekly Semaglutide in Adults with Overweight or Obesity. N Engl J Med. 2021;384:989-1002.

2. Tirzepatide (Mounjaro/Zepbound) — efficacy and treatment profile

Jastreboff AM, Aronne LJ, Ahmad NN, et al., for the SURMOUNT-1 Investigators. Tirzepatide Once Weekly for the Treatment of Obesity. N Engl J Med. 2022;387:205-216.

3. Lean mass loss during GLP-1 treatment — systematic review

Effect of glucagon-like peptide-1 receptor agonists and co-agonists on body composition: systematic review and network meta-analysis. Metabolism. 2024.

4. Hair loss (telogen effluvium) associated with weight loss

Telogen Effluvium Associated With Weight Loss: A Single Center Retrospective Study. Ann Dermatol. 2024.

5. Strength training and protein for preserving muscle mass

Nutritional and exercise interventions in individuals with sarcopenic obesity around retirement age: a systematic review and meta-analysis. 2023.

6. Protein and exercise recommendations in sarcopenic obesity

Exercise and Protein Supplementation Recommendations for Older Adults With Sarcopenic Obesity: A Meta-Review. 2023.

7. Brazilian position statement on pharmacologic obesity treatment

Pharmacologic Treatment of Obesity in Adults and Its Impact on Comorbidities: 2024 Update and Position Statement of Specialists from ABESO and SBEM.

8. Brazilian obesity guidelines (official portal)

Associação Brasileira para o Estudo da Obesidade e da Síndrome Metabólica (ABESO). Diretrizes.

9. Sarcopenia definition and diagnosis — European consensus (EWGSOP2)

Cruz-Jentoft AJ, Bahat G, Bauer J, et al., for the Writing Group for the European Working Group on Sarcopenia in Older People 2 (EWGSOP2). Sarcopenia: revised European consensus on definition and diagnosis. Age Ageing. 2019;48(1):16-31.

10. Sarcopenia and mortality risk — systematic review and meta-analysis

Xu J, Wan CS, Ktoris K, Reijnierse EM, Maier AB. Sarcopenia Is Associated with Mortality in Adults: A Systematic Review and Meta-Analysis. Gerontology. 2022;68(4):361-376.

11. Muscle mass as a predictor of longevity in older adults

Srikanthan P, Karlamangla AS. Muscle Mass Index As a Predictor of Longevity in Older Adults. Am J Med. 2014;127(6):547-553.

12. Grip strength as a mortality predictor — the PURE study

Leong DP, Teo KK, Rangarajan S, et al., for the Prospective Urban Rural Epidemiology (PURE) Study Investigators. Prognostic value of grip strength: findings from the Prospective Urban Rural Epidemiology (PURE) study. Lancet. 2015;386(9990):266-273.

13. Body composition with tirzepatide — SURMOUNT-1 substudy

Look M, Dunn JP, Kushner RF, et al. Body composition changes during weight reduction with tirzepatide in the SURMOUNT-1 study of adults with obesity or overweight. Diabetes Obes Metab. 2025;27(5):2720-2729.

14. Body composition with semaglutide — STEP 1 exploratory analysis

Wilding JPH, Batterham RL, Calanna S, et al. Impact of Semaglutide on Body Composition in Adults With Overweight or Obesity: Exploratory Analysis of the STEP 1 Study.

15. Hypogonadism diagnosis and treatment guideline — Endocrine Society

Bhasin S, Brito JP, Cunningham GR, et al. Testosterone Therapy in Men With Hypogonadism: An Endocrine Society Clinical Practice Guideline. J Clin Endocrinol Metab. 2018;103(5):1715-1744.

16. Effects of testosterone treatment in older men — the Testosterone Trials

Snyder PJ, Bhasin S, Cunningham GR, et al., for the Testosterone Trials Investigators. Effects of Testosterone Treatment in Older Men. N Engl J Med. 2016;374(7):611-624.

17. Cardiovascular safety of testosterone replacement — the TRAVERSE study

Lincoff AM, Bhasin S, Flevaris P, et al., for the TRAVERSE Study Investigators. Cardiovascular Safety of Testosterone-Replacement Therapy. N Engl J Med. 2023.

18. Testosterone replacement and prostate cancer risk — meta-analysis

Cui Y, Zong H, Yan H, Zhang Y. The effect of testosterone replacement therapy on prostate cancer: a systematic review and meta-analysis. Prostate Cancer Prostatic Dis. 2014;17(2):132-143.

19. Chronic insomnia definition and diagnostic criteria

McNamara S, Spurling BC, Bollu PC. Chronic Insomnia. StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; updated March 28, 2025.

20. Insomnia and cardiovascular risk — meta-analysis of prospective studies

Sofi F, Cesari F, Casini A, Macchi C, Abbate R, Gensini GF. Insomnia and risk of cardiovascular disease: a meta-analysis. Eur J Prev Cardiol. 2014;21(1):57-64.

21. Insomnia and hypertension risk — meta-analysis

Li L, Gan Y, Zhou X, et al. Insomnia and the risk of hypertension: A meta-analysis of prospective cohort studies. Sleep Med Rev. 2021;56:101403.

22. Sleep disturbances and type 2 diabetes risk — systematic review and meta-analysis

Anothaisintawee T, Reutrakul S, Van Cauter E, Thakkinstian A. Sleep disturbances compared to traditional risk factors for diabetes development: systematic review and meta-analysis. Sleep Med Rev. 2016;30:11-24.

23. Short sleep duration and obesity risk — meta-analysis

Cappuccio FP, Taggart FM, Kandala NB, Currie A, Peile E, Stranges S, Miller MA. Meta-analysis of short sleep duration and obesity in children and adults. Sleep. 2008;31(5):619-626.

24. Insomnia and dyslipidemia (high cholesterol) — population-based study

Zhan Y, Zhang F, Lu L, et al. Prevalence of dyslipidemia and its association with insomnia in a community based population in China. BMC Public Health. 2014;14:1050.

25. Insomnia and depression risk — meta-analysis of prospective studies

Li L, Wu C, Gan Y, Qu X, Lu Z. Insomnia and the risk of depression: a meta-analysis of prospective cohort studies. BMC Psychiatry. 2016;16:375.

26. Telogen effluvium — pathophysiology, hair cycle, and timeline

Asghar F, Shamim N, Farooque U, Sheikh D, Aqeel R. Telogen Effluvium: A Review of the Literature. Cureus. 2020;12(5):e8320.

27. Alopecia associated with GLP-1 receptor agonists (weight-loss medications) — scoping review

Rojas Lopez RF, Barrera DL, Amaya Muñoz MC, Saavedra Diaz MP. Alopecia as an Emerging Adverse Effect Associated With Glucagon-Like Peptide-1 (GLP-1) Receptor Agonists for Weight Loss: A Scoping Review. Cureus. 2025;17(8):e90021.

28. Iron deficiency and hair loss in women — systematic review and meta-analysis

Treister-Goltzman Y, Yarza S, Peleg R. Iron Deficiency and Nonscarring Alopecia in Women: Systematic Review and Meta-Analysis. Skin Appendage Disord. 2022;8(2):83-92.

29. Hair loss after bariatric surgery — systematic review and meta-analysis

Zhang W, Fan M, Wang C, Mahawar K, Parmar C, Chen W, Yang W; Global Bariatric Research Collaborative. Hair Loss After Metabolic and Bariatric Surgery: a Systematic Review and Meta-analysis. Obes Surg. 2021;31(6):2649-2659.

30. Psychological and quality-of-life impact of hair loss — meta-analysis

Huang CH, Fu Y, Chi CC. Health-Related Quality of Life, Depression, and Self-esteem in Patients With Androgenetic Alopecia: A Systematic Review and Meta-analysis. JAMA Dermatol. 2021;157(8):963-970.

31. Prevalence of low sexual desire by age and sex — British population study

Mitchell KR, Mercer CH, Ploubidis GB, et al. Sexual function in Britain: findings from the third National Survey of Sexual Attitudes and Lifestyles (Natsal-3). Lancet. 2013;382(9907):1817-1829.

32. Low sexual desire and menopause in women — the PRESIDE study

West SL, D'Aloisio AA, Agans RP, Kalsbeek WD, Borisov NN, Thorp JM. Prevalence of Low Sexual Desire and Hypoactive Sexual Desire Disorder in a Nationally Representative Sample of US Women. Arch Intern Med. 2008;168(13):1441-1449.

33. Depression, antidepressants, and sexual dysfunction — review

Kennedy SH, Rizvi S. Sexual dysfunction, depression, and the impact of antidepressants. J Clin Psychopharmacol. 2009;29(2):157-164.

34. Testosterone and sexual desire in women — international consensus position statement

Davis SR, Baber R, Panay N, et al. Global Consensus Position Statement on the Use of Testosterone Therapy for Women. J Clin Endocrinol Metab. 2019;104(10):4660-4666.

35. Semaglutide and risk of erectile dysfunction and hypogonadism — database study

Able C, Liao B, Saffati G, Maremanda A, Applewhite J, Nasrallah AA, Sonstein J, Alzweri L, Kohn TP. Prescribing semaglutide for weight loss in non-diabetic, obese patients is associated with an increased risk of erectile dysfunction: a TriNetX database study. Int J Impot Res. 2025;37(4):315-319.

36. Long-term persistence of hormonal adaptations to weight loss

Sumithran P, Prendergast LA, Delbridge E, et al. Long-term persistence of hormonal adaptations to weight loss. N Engl J Med. 2011;365(17):1597-1604.

37. Weight regain after semaglutide discontinuation — the STEP 4 trial

Rubino D, Abrahamsson N, Davies M, et al. Effect of Continued Weekly Subcutaneous Semaglutide vs Placebo on Weight Loss Maintenance in Adults With Overweight or Obesity: The STEP 4 Randomized Clinical Trial. JAMA. 2021;325(14):1414-1425.

38. Weight regain after tirzepatide discontinuation — the SURMOUNT-4 trial

Aronne LJ, Sattar N, Horn DB, et al. Continued Treatment With Tirzepatide for Maintenance of Weight Reduction in Adults With Obesity: The SURMOUNT-4 Randomized Clinical Trial. JAMA. 2024;331(1):38-48.

39. Lag between physical change and self-image updating — theoretical review

Fava B, Spiezia C, Di Rosa C, Dalla Ragione L, Khazrai YM. When the body changes faster than the brain: a narrative and theoretical review of body schema updating after bariatric surgery. Front Nutr. 2026;13:1874945.

40. Changes in body image over time after bariatric surgery — cohort study

Bosc L, Mathias F, Monsaingeon M, Gronnier C, Pupier E, Gatta-Cherifi B. Long-term changes in body image after bariatric surgery: An observational cohort study. PLoS One. 2022;17(12):e0276167.

41. Weight-related anxiety — development of the Body Mass Anxiety Scale

Styk W, Wojtowicz E, Zmorzynski S. I Don't Want to Be Thin! Fear of Weight Change Is Not Just a Fear of Obesity: Research on the Body Mass Anxiety Scale. Int J Environ Res Public Health. 2023;20(4):2888.

42. Dietary protein intake recommendations for older adults — the PROT-AGE study group

Bauer J, Biolo G, Cederholm T, et al. Evidence-Based Recommendations for Optimal Dietary Protein Intake in Older People: A Position Paper From the PROT-AGE Study Group. J Am Med Dir Assoc. 2013;14(8):542-559.

43. Protein and exercise for optimal muscle function with aging — the ESPEN expert group

Deutz NEP, Bauer JM, Barazzoni R, et al. Protein intake and exercise for optimal muscle function with aging: Recommendations from the ESPEN Expert Group. Clin Nutr. 2014;33(6):929-936.

44. Protein distribution throughout the day and muscle protein synthesis

Mamerow MM, Mettler JA, English KL, et al. Dietary Protein Distribution Positively Influences 24-h Muscle Protein Synthesis in Healthy Adults. J Nutr. 2014;144(6):876-880.

45. Resistance training for older adults — official position statement (NSCA)

Fragala MS, Cadore EL, Dorgo S, Izquierdo M, Kraemer WJ, Peterson MD, Ryan ED. Resistance Training for Older Adults: Position Statement From the National Strength and Conditioning Association. J Strength Cond Res. 2019;33(8):2019-2052.

46. Whey protein supplementation with resistance training in older adults with sarcopenia — meta-analysis

Cuyul-Vásquez I, Pezo-Navarrete J, Vargas-Arriagada C, Ortega-Díaz C, Sepúlveda-Loyola W, Hirabara SM, Marzuca-Nassr GN. Effectiveness of Whey Protein Supplementation during Resistance Exercise Training on Skeletal Muscle Mass and Strength in Older People with Sarcopenia: A Systematic Review and Meta-Analysis. Nutrients. 2023;15(15):3424.